Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.
The May 26 front-page article “Patients face new hurdles to affordable obesity drugs” highlighted significant barriers patients and providers face in accessing GLP-1 and dual GLP-1/GIP receptor agonists (such as Ozempic, Mounjaro, Wegovy and Zepbound) for weight management. However, one critical group whose lives may depend on these medications was absent: individuals with end-stage organ failure.
About letters to the editor
The Post welcomes letters to the editor on any subject, especially those that expand upon the ideas raised by published pieces and those that raise valuable questions about The Post’s practices and choices. Letters should run no more than 400 words, be submitted only to the Post and must be published under your real name. Submit a letter.
What readers are saying
